Novel non-nucleoside HCV NS5B inhibitors exhibit low potential for CYP-mediated drug-drug interactions

被引：0
|
作者：
Sergeeva, Maria [1 ]
LeBrun, Laurie A. [1 ]
Hou, Huiying [1 ]
Kirkovsky, Leo [1 ]
Zhou, Yuefen [1 ]
机构：
[1] Anadys Pharmaceut Inc, San Diego, CA USA
来源：
FASEB JOURNAL | 2009年 / 23卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
749.6
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Mechanism of Inhibition for BMS-791325, a Novel Non-nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
    Rigat, Karen L.
    Lu, Hao
    Wang, Ying-Kai
    Argyrou, Argyrides
    Fanslau, Caroline
    Beno, Brett
    Wang, Yi
    Marcinkeviciene, Jovita
    Ding, Min
    Gentles, Robert G.
    Gao, Min
    Abell, Lynn M.
    Roberts, Susan B.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (48) : 33456 - 33468
  • [42] PATTERNS OF NS5B MUTATIONS IN A 3-DAY CLINICAL TRIAL OF HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR IDX375
    McCarville, Joseph
    Gillum, Joshua M.
    Seifer, Maria
    Dumbrava, Vlada-Tatiana
    Pietropaolo, Keith
    Sullivan-Bolyai, John
    Standring, David N.
    HEPATOLOGY, 2011, 54 : 542A - 543A
  • [43] Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase:: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency
    Beaulieu, PL
    Bös, M
    Bousquet, Y
    DeRoy, P
    Fazal, G
    Gauthier, J
    Gillard, J
    Goulet, S
    McKercher, G
    Poupart, MA
    Valois, S
    Kukolj, G
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (04) : 967 - 971
  • [44] Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D-QSAR and molecular docking studies
    Cao, Hongyu
    Cao, Ran
    Zhang, Huabei
    Zheng, Xuefang
    Gao, Dabin
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (15) : 1462 - 1477
  • [45] Structure-based optimization and derivatization of 2-substituted quinolone-based non-nucleoside HCV NS5B inhibitors with submicromolar cellular replicon potency
    Cheng, Yu
    Shen, Jian
    Peng, Run-Ze
    Wang, Gui-Feng
    Zuo, Jian-Ping
    Long, Ya-Qiu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (12) : 2900 - 2906
  • [46] IDENTIFICATION AND CHARACTERIZATION OF PPI-383, A NEXT GENERATION HCV NS5B NON-NUCLEOSIDE INHIBITOR WITH POTENT ACTIVITY AGAINST ALL MAJOR HCV GENOTYPES
    Colonno, R.
    Huang, N.
    Lau, M.
    Huang, Q.
    Huq, A.
    Peng, E.
    Bencsik, M.
    Zhong, M.
    Li, L.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S464 - S464
  • [47] Design, synthesis, assessment, and molecular docking of novel pyrrolopyrimidine (7-deazapurine) derivatives as non-nucleoside hepatitis C virus NS5B polymerase inhibitors
    Mohamed, Mosaad S.
    Sayed, Amira I.
    Khedr, Mohammed A.
    Soror, Sameh H.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (09) : 2146 - 2157
  • [48] First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients
    Hasanshahi, Zahra
    Hashempour, Ava
    Ghasabi, Farzane
    Moayedi, Javad
    Musavi, Zahra
    Dehghani, Behzad
    Sharafi, Heidar
    Joulaei, Hassan
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [49] Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions
    Khalilieh, Sauzanne
    Yee, Ka Lai
    Sanchez, Rosa
    Stoch, S. Aubrey
    Wenning, Larissa
    Iwamoto, Marian
    CLINICAL DRUG INVESTIGATION, 2020, 40 (10) : 927 - 946
  • [50] First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients
    Zahra Hasanshahi
    Ava Hashempour
    Farzane Ghasabi
    Javad Moayedi
    Zahra Musavi
    Behzad Dehghani
    Heidar Sharafi
    Hassan Joulaei
    BMC Gastroenterology, 21
12345